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were not signiﬁcant in the model. CONCLUSIONS: Medicaid
patients, with COPD, who are African American, older than 40,
with a diagnosis of hypertension, obesity, diabetes, cardiomy-
opathy or myocardial infarction are at signiﬁcantly higher risk
for heart failure. Managed care plans may need to consider those
risk factors in Medicaid patients with COPD.
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OBJECTIVE: This study estimates inpatient, outpatient, and
prescription drugs expenditures and health care utilization for
patients with Chronic Obstructive Pulmonary Disease (COPD).
METHODS: Inpatient and outpatient claims with primary diag-
nosis of COPD-deﬁning diseases (ICD-9 codes 491**, 492**,
496**) from 1998–2002 were extracted from Medstat Mar-
ketscan database and then matched to prescription drug expen-
ditures using unique identiﬁers. Regression models controlled for
age, gender, employment status, health plan type and other vari-
ables. All regression factors mentioned below were signiﬁcant
with p < 0.01. RESULTS: Average per patient annual expendi-
tures was $7874–$11,412 for inpatient service depending on 
the type of health plan; $154–$238 for outpatient visits; and
$85–$151 for prescription drugs. Results also indicated that
gender, age, health care plan type, the region where patient lived
and the patient’s industry type all signiﬁcantly affected health
care expenditures and utilization for COPD care. For example,
women were less likely to be hospitalized or receive outpatient
care, but were more likely to ﬁll COPD-related prescription
drugs. Patients in plans requiring a primary care physician 
referral to receive specialty care (PCP plans) were less likely to
be hospitalized, made fewer outpatient visits and ﬁlled fewer
COPD-related prescriptions. Overall, inpatient expenditures
were 1.2% higher for men and 18% lower for patients enrolled
in PCP plans. Outpatient expenditures were about 3% higher for
men and about 1.7% higher for patients in PCP plans. Prescrip-
tion medication expenditures were about 2% higher for men and
about 19% lower for patients in PCP plans. In all regressions,
older patients had higher expenditures. CONCLUSION: There
is a substantial economic burden associated with COPD which
can potentially be reduced signiﬁcantly by enrolling patient in
PCP plans. Further research is needed to examine why men with
COPD use more health care than women and to assess the
quality of care provided by PCP plans.
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OBJECTIVE: To conduct a beneﬁt-risk assessment comparing
telithromycin with other commonly prescribed therapies for 
the treatment of community-acquired pneumonia (CAP).
METHODS: We developed a model to quantify the beneﬁts and
risks of telithromycin versus other common therapies for CAP
in terms of quality-adjusted days (QAD) gained. A typical 
65-year-old patient was assumed to receive amoxicillin, clar-
ithromycin, or telithromycin for the treatment of acute CAP.
Drug efﬁcacy, drug resistance, adverse event (AE) rates and
sequelae, and utility decrements associated with CAP and AEs
were estimated from published clinical trials and other secondary
sources. Beneﬁts of telithromycin versus other therapies were
assessed by estimating the gain in QAD due to successful treat-
ment of CAP. Risks were assessed by estimating the QAD 
lost due to treatment-related AEs (liver toxicity, prolonged QT
interval, diarrhea, and blurry vision) and their sequelae. The net
beneﬁt of telithromycin was calculated by summing expected
beneﬁts and risks over the 21-day period after treatment initia-
tion (including lifetime QAD lost due to death and chronic 
conditions). We used a second-order Monte Carlo simulation 
to evaluate the effect of uncertainty in key model parameters on
our ﬁndings. RESULTS: Patients treated with telithromycin
versus amoxicillin are expected to gain 31.01 QAD due to suc-
cessful treatment of CAP and 0.26 QAD due to AEs. Versus clar-
ithromycin, telithromycin patients lose 0.01 QAD to AEs;
however, the net beneﬁt is a gain of 13.09 QAD. Probabilistic
sensitivity analyses showed telithromycin to be at least as bene-
ﬁcial as amoxicillin and clarithromycin in 85% and 68% of
10,000 iterations, respectively. CONCLUSIONS: Telithromycin
demonstrated a net beneﬁt in terms of QAD gained versus both
amoxicillin and clarithromycin despite slightly higher risks due
to AEs than clarithromycin. In general, QAD lost due to AEs
were negligible compared to the potential beneﬁts from success-
ful treatment of CAP with telithromycin.
PRS15
PREDICTING EXACERBATION EVENTS IN COPD USING
ADMINISTRATIVE DATA
Nelson LS1, Mapel DW1, Lydick E1, Marton J2
1Lovelace Clinic Foundation, Albuquerque, NM, USA; 2Pﬁzer Inc,
New York, NY, USA
OBJECTIVES: Cost-effectiveness modeling in COPD is often
problematic because the utilization data is usually derived from
participants in randomized clinical trials, who may not be very
representative of patients treated in the general population. We
used the administrative data of a large cohort of COPD patients
treated by one managed care system to see whether exacerbation
events could be predicted with sufﬁcient accuracy to be used in
cost modeling. METHODS: COPD patients under usual care
who were continuously enrolled in the Lovelace Health Plan for
selected, seasonal 6-month blocks during the study’s observation
period (September 1, 2000 to August 31, 2003) were identiﬁed
using administrative data and a cross-sectional-pooling design
(N = 2850). Subsequent exacerbation events, deﬁned as hospital
admissions or outpatient encounters with a primary respiratory
diagnosis, were captured from the database. Logistic regression
models were then developed to identify factors associated with
exacerbations. RESULTS: Approximately 46% of the cohort 
had one or more exacerbations during the observation period.
Factors signiﬁcantly associated with an exacerbation (p < 0.05)
included age, the number of pulmonary and non-pulmonary out-
patient encounters, the total number of prescription ﬁlls, having
one or more serious comorbidities, ever having an additional
diagnosis of asthma, the season of the prior 6 month period as
well as having had an exacerbation as well as many two-way
interaction terms. The model was able to predict the status of
patients with a good degree of accuracy (69% concordant, 30%
discordant, 1% tied). CONCLUSIONS: COPD exacerbation
events can be reliably predicted from the utilization data com-
monly found in health system administrative databases. The pre-
dicted probabilities from these models can be used to estimate
transition probabilities in Markov and similar cost-effectiveness
models.
